The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Abstract
PURPOSE: To determine the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) in combination with interferon-gamma (IFN) and melphalan as induction therapy to render tumors resectable and avoid amputation in patients with nonresectable extremity soft tissue sarcomas (STS). PATIENTS AND METHODS: Among 55 patients with 30 primary and 25 recurrent sarcomas, there were 48 high-grade and seven grade 1 sarcomas (very large, recurrent, or multiple). The composition of this series of patients is unusual: 13 patients (24%) had multifocal primary sarcomas or multiple recurrent tumors; tumors were very large (median, 18 cm); and nine patients (16%) had known systemic metastases. IFN was administered subcutaneously on the 2 days before ILP with TNF, IFN, and melphalan. A delayed marginal resection of the tumor remnant was usually performed 2 to 3 months after ILP. RESULTS: A major tumor response was seen in 87% of patients and rendered the sarcomas resectable in most cases. Clinical response rates were as follows: 10 (18%) completes responses (CRs), 35 (64%) partial responses (PRs), and 10 (18%) no change (NC). Final outcome was defined as follows by clinical and pathologic response: 20 (36%) CRs, 28 (51%) PRs, and seven (13%) NC. Limb salvage was achieved in 84% (follow-up duration, 20+ to 50+ months). In 39 patients, resection of the tumor remnant (n = 31) or of two to eight tumors (n = 8) after ILP was performed; local recurrence developed in five (13%). When no resection was performed (multiple tumors or systemic metastases), local recurrences were frequent (five of 16), but limb salvage was often achieved as patients died of systemic disease. Regional toxicity was limited and systemic toxicity minimal to moderate with no toxic deaths. Histology showed hemorrhagic necrosis; angiographies showed selective destruction of tumor-associated vessels. CONCLUSION: ILP with TNF, IFN, and melphalan is a safe and highly effective induction biochemotherapy procedure that can achieve limb salvage in patients with nonresectable extremity STS. TNF is an active anticancer drug in humans in the setting of ILP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Sugarman, B. J., Aggarwal, B. B., Hass, P. E., Figari, I. S., Palladino, M. A., & Shepard, H. M. (1985) · Science · doi:10.1126/science.3933111 · Cited by 1,580
Trojani, M., Contesso, G., Coindre, J. M., Rouesse, J., Bui, N. B., De Mascarel, A., Goussot, J. F., David, M., Bonichon, F., & Lagarde, C. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910330108 · Cited by 1,317
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Spriggs, D. R., Sherman, M. L., Michie, H., Arthur, K. A., Imamura, K., Wilmore, D., Frei, E., & Kufe, D. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1039 · Cited by 308
(1986) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/76.6.1113 · Cited by 295
Asher, A., Mulé, J. J., Reichert, C. M., Shiloni, E., & Rosenberg, S. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.963 · Cited by 289
High-grade soft tissue sarcomas of the extremities
Potter, D. A., Kinsella, T., Glatstein, E., Wesley, R., White, D. E., Seipp, C. A., Chang, A. E., Lack, E. E., Costa, J., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19860701)58:1<190::aid-cncr2820580133>3.0.co;2-5 · Cited by 282
Toxic effect of tumor necrosis factor on tumor vasculature in mice.
Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., & Urushizaki, I. (1988) · PubMed · Cited by 237
Feinberg, B., Kurzrock, R., Talpaz, M., Blick, M., Saks, S., & Gutterman, J. U. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1328 · Cited by 221
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
Chapman, P. B., Lester, T. J., Casper, E. S., Gabrilove, J. L., Wong, G. Y., Kempin, S. J., Gold, P. J., Welt, S., Warren, R. S., & Starnes, H. F. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.12.1942 · Cited by 214
Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas.
Nawroth, P., Handley, D., Matsueda, G., De Waal, R., Gerlach, H., Blohm, D., & Stern, D. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.2.637 · Cited by 162
Renard, N., Liénard, D., Lespagnard, L., Eggermont, A. M. M., Heimann, R., & Lejeune, F. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570508 · Cited by 144
Self-citationThom, A. K., Alexander, H. R., Andrich, M. P., Barker, W. C., Rosenberg, S. A., & Fraker, D. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.264 · Cited by 103
Swaak, A. J. G., Liénard, D., Koops, H. S., Lejeune, F. J., & Eggermont, A. M. M. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb00735.x · Cited by 31
Self-citation
Cited by
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 842
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 701
Self-citation
Metadata
- Authors
- Eggermont, A. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., & Lejeune, F. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-10
- Volume
- 14
- Issue
- 10
- Pages
- 2653-2665
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1890068101
- Cited by
- 398
- References
- 15
- FWCI
- 25.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.